Growth Hormone Treatment in Children With Hypophosphatemic Rickets
NCT ID: NCT02720770
Last Updated: 2016-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
19 participants
INTERVENTIONAL
2006-01-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
NCT00473187
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
NCT01973244
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
NCT01110928
French National Registry of Children Born Small for Gestational Age Treated With Somatropin
NCT01578135
Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)
NCT00597480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
norditropine simplex
norditropine simplex
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
norditropine simplex
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* height SDS \< 2
* at least two years of treatment with oral phosphate and calcitriol
Exclusion Criteria
* growth hormone deficiency
* hyperparathyroidism, nephrocalcinosis, renal insufficiency
* associated disease
* previous treatment with growth hormone
3 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bicetre Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessia Usardi
Professor
References
Explore related publications, articles, or registry entries linked to this study.
Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, Linglart A. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Horm IGF Res. 2017 Oct;36:11-15. doi: 10.1016/j.ghir.2017.08.001. Epub 2017 Aug 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RBM 03-47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.